Transaction

Funds granted during the incubation phase will primarily be used to develop an innovative test for the diagnosis of perinatal asphyxia (oxygen supply deficit) and brain damage in newborns.

Company

The InfanDx group develops diagnostic products based on biomarkers derived from metabolomics research. Lead product is a diagnostic test on perinatal asphyxia (oxygen deficit during birth) and subsequent brain damage. The test closes the gap between a large and unspecific risk group of complications during birth and the already available and reimbursed therapy. Additionally, current development of neuroprotective drugs increases the strong medical need for an early diagnostic test to target therapy on those newborn babies in need.

or additional information on INFANDX: www.infandx.de